DOI QR코드

DOI QR Code

Pneumocystis jirovecii pneumonia in pediatric patients: an analysis of 15 confirmed consecutive cases during 14 years

  • Kim, Kyung-Ran (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jong Min (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Ji-Man (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Yae-Jean (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2015.07.18
  • Accepted : 2015.12.29
  • Published : 2016.06.15

Abstract

Purpose: Pneumocystis jirovecii pneumonia occurs in various immunocompromised patients. Despite the prophylaxis strategies in clinical practice, certain patients develop P. jirovecii pneumonia. This study was performed to investigate pediatric cases with P. jirovecii pneumonia in a single center. Methods: We identified pediatric patients younger than 19 years with microbiologically confirmed P. jirovecii pneumonia from January 2000 to February 2014. A retrospective chart review was performed. Results: Fifteen episodes of P. jirovecii pneumonia in 14 patients were identified with median age of 8.3 years (range, 0.4-18.6 years). Among these patients, 11 patients had hematology-oncology diseases, 2 had primary immunodeficiency disorders (one with severe combined immunodeficiency and the other with Wiskott Aldrich syndrome), 1 had systemic lupus erythematosus and 1 received kidney transplant. Four patients were transplant recipients; 1 allogeneic and 2 autologous hematopoietic cell transplant and 1 with kidney transplant. The median absolute lymphocyte count at the diagnosis of P. jirovecii pneumonia was $5,156cells/mm^3$ (range, $20-5,111cells/mm^3$). In 13 episodes (13 of 15, 86.7%), patients were not receiving prophylaxis at the onset of P. jirovecii pneumonia. For treatment, trimethoprim/sulfamethoxazole was given as a main therapeutic agent in all 15 episodes. Steroid was given in 9 episodes (60%). Median treatment duration was 15 days (range, 4-33 days). Overall mortality at 60 days was 35.7% (5 of 14). Conclusion: Majority of our patients developed P. jirovecii pneumonia while not on prophylaxis. Continuous efforts and more data are needed to identify high risk patients who may get benefit from P. jirovecii pneumonia prophylaxis.

Keywords

References

  1. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334:519-22. https://doi.org/10.1038/334519a0
  2. Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis 2005;41:1752-5. https://doi.org/10.1086/498150
  3. Caselli D, Petris MG, Rondelli R, Carraro F, Colombini A, Muggeo P, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 2014;164:389-92.e1. https://doi.org/10.1016/j.jpeds.2013.10.021
  4. Gilroy SA, Bennett NJ. Pneumocystis pneumonia. Semin Respir Crit Care Med 2011;32:775-82. https://doi.org/10.1055/s-0031-1295725
  5. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25:297-317. https://doi.org/10.1128/CMR.00013-12
  6. Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJ, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26. https://doi.org/10.1056/NEJM197712292972602
  7. Bollee G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007;132:1305-10. https://doi.org/10.1378/chest.07-0223
  8. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006;(3):CD006150.
  9. Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 2013;14:87. https://doi.org/10.1186/1465-9921-14-87
  10. Beltz K, Kramm CM, Laws HJ, Schroten H, Wessalowski R, Gobel U. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Padiatr 2006;218:177-9. https://doi.org/10.1055/s-2006-933433

Cited by

  1. Characteristic Features of Pneumocystis Pneumonia in Pediatric Acute Lymphoblastic Leukemia vol.25, pp.2, 2016, https://doi.org/10.15264/cpho.2018.25.2.154